Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth

The post Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth appeared on BitcoinEthereumNews.com.

Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170. AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) in…

Leave a Reply

Your email address will not be published. Required fields are marked *